Vulvar Cancer Market Report 2026

Vulvar Cancer Market Overview

• Vulvar Cancer market size has reached to $0.62 billion in 2025 • Expected to grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 8.8% • Growth Driver: Rising Investments In Oncology Research And Medicine A Catalyst For Growth In The Market • Market Trend: Advancements In Alpha-Radiation Cancer Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Vulvar Cancer Market?

Vulvar cancer refers to cancer that develops in the vulva, the external part of the female genitalia. It typically begins in the skin or tissues of the vulva and can involve the labia, clitoris, or vaginal opening. The most common type is squamous cell carcinoma, often linked to human papillomavirus (HPV) infection. Symptoms may include itching, pain, and visible growths or sores on the vulva. The main vulvar cancer types are vulvar squamous cell carcinoma, vulvar melanoma, adenocarcinoma, and basal cell carcinoma. Vulvar squamous cell carcinoma (SCC) is a type of cancer that begins in the squamous cells of the vulva, the outer part of the female genitalia. It can be treated using chemotherapy, surgery, laser surgery, excision, skinning vulvectomy, radical vulvectomy, radiation therapy and biologic therapy and is distributed through online and offline channels. It is used by various end users such as hospitals and clinics, research and academic institutes, and others.

What Is The Vulvar Cancer Market Growth Forecast?

The vulvar cancer market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing investments in precision oncology, rising adoption of biologic and immunotherapies, expansion of HPV vaccination impact monitoring, increasing focus on personalized treatment planning, advancements in diagnostic imaging technologies. Major trends in the forecast period include increasing adoption of targeted cancer therapies, rising use of minimally invasive surgical procedures, growing focus on early diagnosis and screening, expansion of multimodal treatment approaches, enhanced integration of personalized oncology care.

Global Vulvar Cancer Market Segmentation

1) By Cancer Type: Vulvar Squamous Cell Carcinoma, Vulvar Melanoma, Adenocarcinoma, Basal Cell Carcinoma 2) By Treatment Type: Chemotherapy, Surgery, Laser Surgery, Excision, Skinning Vulvectomy, Radical Vulvectomy, Radiation Therapy, Biologic Therapy 3) By Distribution Channel: Online Channel, Offline Channel 4) By End Users: Hospitals And Clinics, Research And Academic Institutes, Other End Users Subsegments: 1) By Vulvar Squamous Cell Carcinoma: Keratinizing Squamous Cell Carcinoma, Non-Keratinizing Squamous Cell Carcinoma, Verrucous Carcinoma 2) By Vulvar Melanoma: Mucosal Melanoma, Acral Lentiginous Melanoma, Nodular Melanoma 3) By Adenocarcinoma: Bartholin Gland Adenocarcinoma, Extramammary Paget’s Disease-Associated Adenocarcinoma, Sweat Gland Adenocarcinoma 4) By Basal Cell Carcinoma: Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Morpheaform (Sclerosing) Basal Cell Carcinoma

What Are The Drivers Of The Vulvar Cancer Market?

The increasing investments on oncology research and medicine is expected to propel the growth of the vulvar cancer market going forward. Investments in oncology research and medicine refer to financial allocations made by governments, pharmaceutical companies, research institutions, and private investors to advance the understanding, prevention, diagnosis, and treatment of cancer. The increasing investments in oncology research and medicine are due to the rising global cancer burden, advancements in precision medicine, growing demand for innovative therapies, expanding clinical trials, government and private funding initiatives, and the development of targeted and immunotherapy treatments. Investments in oncology research and medicine support vulvar cancer by driving advancements in early diagnosis, enhancing treatment options such as targeted therapies and immunotherapy, funding clinical trials for more effective drugs, improving pediatric cancer care infrastructure, and fostering innovative research to better understand the disease’s biology and progression. For instance, in May 2024, according to the IQVIA, an India-based information technology company providing advanced analytics, global spending on cancer medicine rose to $223 billion in 2023, marking a $25 billion increase from 2022, and is expected to reach $409 billion by 2028. Therefore, the increasing investments on oncology research and medicine drives the vulvar cancer industry. The growing focus on personalized medicine is expected to propel the growth of the vulvar cancer market going forward. Personalized medicine refers to tailoring medical treatment to individual patients based on their genetic, environmental, and lifestyle factors. Personalized medicine is growing to improve treatment effectiveness and minimize adverse effects by addressing individual patient differences. Personalized medicine helps vulvar cancer by tailoring treatments based on the patient's genetic profile, improving outcomes and minimizing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the vulvar cancer industry.

Key Players In The Global Vulvar Cancer Market

Major companies operating in the vulvar cancer market are F. Hoffmann-La Roche Ltd, Merck And Co., Bristol‑Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Regeneron Pharmaceuticals Inc., Intuitive Surgical Operations Inc., Elekta AB, Accuray Incorporated, Xencor, ISA Pharmaceuticals BV, Alpha Tau Medical Ltd, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc, Eli Lilly and Company, AbbVie Inc, Astellas Pharma Inc, Takeda Pharmaceutical Company Ltd, Bayer AG, Ipsen, Gilead Sciences Inc

Global Vulvar Cancer Market Trends and Insights

Major companies operating in the vulvar cancer market are focusing on innovations in cancer therapy, such as alpha-radiation cancer therapy, to enhance treatment efficacy and patient outcomes. Alpha-radiation cancer therapy refers to a treatment that delivers targeted alpha particles to tumor cells, causing localized damage to cancerous tissue while minimizing harm to surrounding healthy tissue. For instance, in May 2023, Alpha Tau Medical Ltd., an Israel-based company, announced the first use of its Alpha DaRT alpha-radiation cancer therapy for the treatment of squamous cell carcinoma of the vulva. The study, conducted at Addenbrooke's Hospital within the Cambridge University Hospitals NHS Foundation Trust, aims to recruit 10 participants to evaluate the safety and efficacy of the therapy. Alpha DaRT provides a targeted, minimally invasive approach, showcasing its potential as a non-surgical treatment option for vulvar cancer.

Regional Outlook

North America was the largest region in the vulvar cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Vulvar Cancer Market?

The vulvar cancer market consists of revenues earned by entities by providing services such as diagnostic testing, clinical consultations, immunotherapy, targeted therapy, and post-treatment care and monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The vulvar cancer market also includes sales of pharmaceuticals, immunotherapy drugs, targeted therapy medications, diagnostic kits, and medical devices for tumor detection and monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vulvar Cancer Market Report 2026?

The vulvar cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vulvar cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.